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Abstract
Background: Circulating 25-hydroxyvitamin D [25(OH)D] concentration is inversely associated with peripheral arterial
disease and hypertension. Vascular remodeling may play a role in this association, however, data relating vitamin D
level to specific remodeling biomarkers among ESRD patients is sparse. We tested whether 25(OH)D concentration is
associated with markers of vascular remodeling and inflammation in African American ESRD patients.
Methods: We conducted a cross-sectional study among ESRD patients receiving maintenance hemodialysis within
Emory University-affiliated outpatient hemodialysis units. Demographic, clinical and dialysis treatment data were
collected via direct patient interview and review of patients records at the time of enrollment, and each patient
gave blood samples. Associations between 25(OH)D and biomarker concentrations were estimated in univariate
analyses using Pearson’s correlation coefficients and in multivariate analyses using linear regression models. 25(OH)
D concentration was entered in multivariate linear regression models as a continuous variable and binary variable
(<15 ng/ml and ≥15 ng/ml). Adjusted estimate concentrations of biomarkers were compared between 25(OH) D
groups using analysis of variance (ANOVA). Finally, results were stratified by vascular access type.
Results: Among 91 patients, mean (standard deviation) 25(OH)D concentration was 18.8 (9.6) ng/ml, and was low
(<15 ng/ml) in 43% of patients. In univariate analyses, low 25(OH) D was associated with lower serum calcium,
higher serum phosphorus, and higher LDL concentrations. 25(OH) D concentration was inversely correlated with
MMP-9 concentration (r = -0.29, p = 0.004). In multivariate analyses, MMP-9 concentration remained negatively
associated with 25(OH) D concentration (P = 0.03) and anti-inflammatory IL-10 concentration positively correlated
with 25(OH) D concentration (P = 0.04).
Conclusions: Plasma MMP-9 and circulating 25(OH) D concentrations are significantly and inversely associated
among ESRD patients. This finding may suggest a potential mechanism by which low circulating 25(OH) D
functions as a cardiovascular risk factor.
Background
The chronic pro-inflammatory state of end-stage renal
disease (ESRD) is associated with increased risk for cardi-
ovascular disease and death [1-3]. Observational studies
suggest an inverse association between circulating 25-
hydroxyvitamin D [25(OH) D] concentration and serum
inflammatory biomarkers. Low 25(OH)D concentrations
are associated with elevated tumor necrosis factor-alpha
(TNF-a) concentrations [4], and randomized controlled
studies among critically ill patients and those with con-
gestive heart failure report that vitamin D supplementa-
tion leads to significant reductions in interleukin 6 ( IL-
6) and C-reactive protein (CRP) concentrations [5], and
resulted in lower tumor necrosis factor-alpha (TNF-a)
and increased anti-inflammatory IL-10 concentrations
[6]. However, few studies have addressed the association
between 25(OH)D concentration and increased inflam-
mation on biomarkers of vascular remodeling. Matrix
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metalloproteinases (MMP’s) are important in extracellu-
lar matrix remodeling, are major effector molecules of
inflammatory cells, and play a key role in many vascular
diseases, including hypertension and aneurysm formation
[7,8]. Recent in vitro studies indicate that vitamin D
down-regulates MMP-9 production by TNF-a [9] and
suppresses production of MMP-7 and MMP-9 [10-12].
Moreover, MMP-2 and MMP-9 activation are associated
with collagen deposition and cardiac fibrosis [13].
Previous studies document the high prevalence of 25
(OH) D deficiency within the U.S. ESRD and general
population [14,15], and the association of 25(OH)D defi-
ciency with vascular disorders [16,17]. Therefore, exami-
nation of the relationship between circulating 25(OH)D
and biomarkers of vascular remodeling is warranted, as
identification of a link between 25(OH) D concentration
and vessel remodeling may suggest a mechanism for
vitamin D deficiency as a risk factor for cardiovascular
disease, and with further study, may offer promising
therapy to improve vascular function among chronic
kidney disease and ESRD patients.
We sought to determine whether circulating 25(OH)
D concentration is associated with serum markers of
vascular remodeling and inflammation in a cross-sec-
tional study of prevalent hemodialysis African American
patients.
Methods
Study Population
Adult ESRD patients receiving in-center maintenance
hemodialysis at one of six Emory University-affiliated
Davita dialysis centers between September 2006-Novem-
ber 2008, were eligible to enroll in the study. The
majority of patients within the Emory dialysis centers
are African American; of 94 patients enrolled, 91 were
AA, thus we limited our analyses to AA patients.
Patients were excluded from the study for the following
reasons: 1) presence of known malignancy or active vas-
culitis; 2) evidence of current infection or inflammation;
or 3) current or recent use of steroids, calcineurin inhi-
bitors or antimetabolite medications (methotrexate,
azathioprine, 5-fluorouracil, mercaptopurine, sulfadia-
zine). These exclusion criteria were chosen because they
provide inflammatory or anti-inflammatory therapy that
could alter the association between vitamin D and
inflammatory markers. Demographic, clinical and dialy-
sis treatment data were collected via direct patient inter-
view and review of patients records at the time of
enrollment, and each patient gave baseline blood sam-
ples. The Institutional Review Board (IRB) of Emory
University Medical Center approved the study protocol
and informed consent was obtained from each patient
prior to study enrollment. Human subjects procedures
followed were in accordance with the ethical standards
of the institutional IRB and with the Helsinki Declara-
tion of 1975.
Definition of variables
All assessments were conducted at a single baseline visit.
We analyzed several covariates including age, gender,
self-reported race, length of time on dialysis, body mass
index (BMI), smoking status (never, former current),
vascular access type (arteriovenous fistula, arteriovenous
graft, central venous catheter), season of blood collec-
tion, and activated vitamin D treatment. Comorbidities
included diabetes (defined by use of diabetes medica-
tions), hypertension, stroke or transient ischemic event,
congestive heart failure, peripheral arterial disease
(PAD), and HIV or AIDS. Results of calcium, phos-
phorus, intact PTH, albumin, hemoglobin, KT/V (used
to quantify hemodialysis adequacy), total cholesterol,
LDL and HDL cholesterol, and triglycerides obtained
within two weeks of the baseline blood sample measure-
ment were abstracted from the outpatient dialysis
records and included in the analysis.
Study Measurements
Serum Cytokine Measurement
All patients received hemodialysis treatment three times
per week. Blood for the analysis of serum biomarkers
was drawn specifically for this study protocol, and was
obtained before a routine, midweek hemodialysis session
within 5 days of study enrollment. After collection,
serum and plasma were aliquoted and stored at -80 C
for subsequent analysis.
All assays were performed on plasma as directed by
the manufacturer and samples were centrifuged for 10
minutes at 10000rpm before testing. All the assays had
quality controls, plasma controls and a non-plasma sam-
ple that was added to each plate. The dilution of the
samples (always done with the Calibration diluent in
which the Standard Cocktail was reconstituted )
depended on the individual assays and of the expected
concentration range for the samples tested.
The Fluorokine® MultiAnalyte Profiling (MAP) Kits
from R&D Systems (Minneapolis, USA) were used to
determine the concentration of analytes. The Fluoro-
kine® MAP MultiAnalyte Profiling Human MMP Base
Kit (R&D Systems) was used to determine the matrix
metalloproteinase 9 (MMP-9) and MMP-2 concentra-
tions (the inter-assay variability is 3.0% and 6.2% respec-
tively). Il-6 and Il-10 concentrations were measured with
the Fluorokine® MAP MultiAnalyte Profiling Human
Base Kit A (R&D Systems) (the inter-assay variability is
4.6% and 5.2% respectively). The CardioPhase hsCRP
reagents from Siemens Diagnostics (Dade Behring pro-
duct) were used to determine the concentration of
hsCRP in plasma samples on a BNII (nephelometry
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systems) System. The Internal Quality Controls (Controls
SL/1 and SL/2 - lower-higher range of CRP) and Stan-
dard SL curve were run with the assay.
25(OH)D Measurement
Serum 25(OH) D concentrations were measured using
chemiluminescence immunoassay (Diasorin Inc, Still-
water, MD, USA; coefficient of variation over multiple
runs 6.3-12.9%) by ARUP Laboratories (Salt Lake City,
UT). 25(OH) D concentration was categorized using a
cutoff of 15 ng/ml, the point below which there is an
increased risk for cardiovascular events [18,19].
Statistical Analysis
Categorical variables were reported by using the number or
percent of observations. Continuous variables were
expressed as means with standard deviations. For compara-
tive evaluations, Chi-square tests (Fisher’s exact test when
appropriate) and student unpaired independent t tests were
performed for categorical and continuous variables, respec-
tively. Distribution figures and Kolmogorov-Smirnov tests
were used to assess inflammatory marker normality. Non-
normally distributed markers were successfully normalized
by natural logarithmic transformation. We used figures
plots to verify that relationships, if any, between biomarkers
and 25(OH)D concentrations were linear. Associations
between 25(OH)D and biomarker concentrations were first
estimated in univariate analyses using Pearson’s correlation
coefficients and corresponding P values.
To adjust for possible confounding of these associations
we then used multivariate linear regression models.
Included in the models were previously reported confoun-
ders as well as variables significant at the 5% level from
the univariate analyses. 25(OH) D concentration was first
entered in multivariate linear regression models as a con-
tinuous variable. Adjusted associations between continu-
ous vitamin D concentration and biomarkers were
reported as beta regression coefficients where the null
value (b = 0) represented no association. We then categor-
ized 25(OH) D using a binary variable (<15 ng/ml and ≥15
ng/ml). Adjusted estimate concentrations of biomarkers
were compared between 25(OH) D groups using analysis
of variance (ANOVA) with SAS generalized linear model
procedures. Finally, results were stratified by vascular
access type. Two-tailed P values P < 0.05 were considered
statistically significant. All analyses were performed using
SAS version 9.2 (SAS Institute, Cary, NC, USA).
Results
Patient Characteristics
The characteristics of the entire study cohort and of
those classified by serum 25(OH) D concentrations are
summarized in Table 1. Lower 25(OH) D concentration
was significantly associated with lower serum calcium,
higher serum phosphorus, and higher LDL
concentration. There were no significant differences in
other characteristics between vitamin D status groups.
Among the study cohort, all subjects were treated with
activated (D3) vitamin D, with the exception of 17 sub-
jects, who took no form of vitamin D (activated or
nutritional), and 3 subjects who took only nutritional
(D2) vitamin D. The characteristics of the cohort by vas-
cular access type are summarized in Table 2. Vascular
access type was significantly associated with diabetes,
stroke or TIA, HIV or AIDS, 25(OH)D and hemoglobin
concentrations.
Serum 25(OH) D Concentrations
Mean 25(OH) D concentration was 18.8 ± 9.6 ng/ml.
Thirty-nine (42.9%) subjects had a 25(OH) D concentra-
tion <15 ng/ml (Table 1). The mean serum 25(OH) D
concentration of subjects in the higher (≥15 ng/ml) and
lower (<15 ng/ml) vitamin D category were 24.5 ± 9.0
ng/ml and 11.1 ± 1.9 ng/ml, respectively.
Serum Inflammatory Markers
Continuous 25(OH) D
25(OH) D concentration was inversely and significantly
correlated with MMP-9 concentration (r = -0.29, p =
0.004) (Figure 1), while the remaining biomarkers were
not associated with 25(OH) D by correlation (Pearson)
analysis.
Categorical 25(OH) D
The distribution of serum inflammatory markers by 25
(OH) D concentration are shown in Table 3. In the uni-
variate analyses and compared to patients with 25(OH)
D ≥15 ng/ml, MMP-9 and CRP concentrations were sig-
nificantly greater among subjects with 25(OH)D < 15
ng/ml. The remaining inflammatory markers were not
associated with 25(OH)D categories.
We compared the difference in MMP-9 concentration
between the lowest and highest 25(OH) D groups (Fig-
ure 2). Compared to the highest group and after adjust-
ment for smoking, gender, BMI, age, diabetes, season
and activated vitamin D treatment, the log MMP-9 con-
centration was greater in the lowest 25(OH)D group (P
= 0.046). For every unit increase in 25(OH) D concen-
tration, there was a log decrease in pro-inflammatory
MMP-9 concentration of 0.018 pg/ml (p = 0.03), while
there was a log increase in anti-inflammatory IL-10 con-
centration of 0.02 pg/ml (p = 0.04) (Table 4).
Upon stratification of vascular access type (arteriovenous
fistula (AVF) vs. arteriovenous graft (AVG)), it appears that
the association between 25(OH) D concentration and
MMP-9 was mostly driven by AVG’s, as 25(OH)D and
MMP-9 and IL-10 no longer remained associated among
AVF users. In contr ast, for every unit increase in 25(OH)
D concentration, the log concentration of MMP-9
decreased by 0.052 pg/ml (P = 0.002) among patients using
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an AVG, while the association of IL-10 to 25(OH) D no
longer remained significant among AVG users (Table 5).
Discussion
Our results indicate that plasma MMP-9 expression is
inversely and independently associated with circulating
25(OH) D concentration among ESRD patients. We also
found anti-inflammatory IL-10 concentration to be asso-
ciated with 25(OH) D concentration. This is the first
report to our knowledge to assess the relationship of 25
(OH)D concentration with MMP-9 and IL-10 in an
ESRD population, and may help to shed light on
Table 1 Characteristics of African American participants by circulating 25(OH) D concentration
Characteristic All patients 25(OH) D < 15 ng/ml 25(OH) D ≥ 15 ng/ml
N = 91 N = 39 N = 52 p value
Age (years) 59.3 ± 12.4 56.4 ± 12.6 61.4 ± 12.0 0.05
Sex 0.27
Female 43 (47.3) 21 (48.5) 22 (51.2)
Male 48 (52.7) 18 (37.5) 30 (62.5)
Dialysis vintage (yrs) 5.7 ± 4.1 6.2 ± 4.5 5.3 ± 3.9 0.33
KT/V* 1.4 ± 0.3 1.4 ± 0.2 1.5 ± 0.4 0.38
Body mass index (kg/m2) 0.10
Under (<18.5) 1 (1.2) 0 (0.0) 1 (100.0)
Normal (18.5 to <25) 23 (26.7) 6 (26.09) 17 (73.9)
Overweight (25 to <30) 37 (43.0) 18 (48.6) 19 (51.4)
Obese (> = 30) 25 (29.1) 14 (56.0) 11 (44.0)
Smoking status 0.08
Never 55 (60.4) 28 (50.9) 27 (49.09)
Former 23 (25.7) 7 (30.4) 16 (69.57)
Current 13 (14.3) 4 (30.8) 9 (69.23)
Vascular access type 0.34
AVF 38 (41.8) 13 (34.2) 25 (65.8)
Graft 44 (48.4) 21 (47.7) 23 (52.3)
Catheter 9 (9.0) 5 (55.6) 4 (44.4)
Activated vitamin D treatment 39 (42.9) 27 (29.7) 44 (48.3) 0.08
Comorbidities
Diabetes 45 (49.4) 23 (51.1) 22 (48.9) 0.11
Hypertension 89 (97.8) 38 (42.7) 51 (57.3) 0.84
Stroke or TIA 16 (17.6) 10 (62.5) 6 (37.5) 0.08
Congestive heart failure 21 (23.1) 9 (42.9) 12 (57.1) 0.99
Peripheral arterial disease 13 (14.3) 7 (53.9) 6 (46.1) 0.79
HIV or AIDS 3 (3.3) 0 (0.0) 3 (100.0) 0.26
Laboratory tests
25(OH)D level (ng/ml) 18.8 ± 9.6 11.1 ± 1.9 24.5 ± 9.0
Calcium (mg/dl) 8.8 ± 0.8 8.5 ± 0.9 9.0 ± 0.8 <0.001
Phosphorus (mg/dl) 5.3 ± 2.0 5.8 ± 1.8 5.0 ± 2.1 0.05
intact PTH (pg/dl) 478.5 ± 537.09 569.9 ± 693.5 409.9 ± 373.6 0.16
Albumin (g/dl) 3.9 ± 0.4 3.9 ± 0.1 3.9 ± 0.1 0.74
Alkaline Phosphatase (U/L) 143.0 ± 113.0 164.9 ± 53.0 126.5 ± 66.7 0.15
Hemoglobin (g/l) 12.1 ± 1.4 12.0 ± 1.5 12.2 ± 1.3 0.63
Total Cholesterol (mg/dl) 154.4 ± 32.8 160.6 ± 35.6 149.7 ± 29.9 0.13
Triglycerides (mg/dl) 133.2 ± 75.3 135.6 ± 66.0 131.3 ± 82.6 0.79
HDL cholesterol (mg/dl) 48.1 ± 19.4 44.4 ± 15.8 51.0 ± 21.6 0.12
LDL cholesterol (mg/dl) 79.1 ± 31.8 87.1 ± 36.5 72.8 ± 26.3 0.04
Results are expressed as number (%) or mean ± standard deviation
*KT/V = dialysis adequacy
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mechanisms by which vitamin D deficiency is associated
with an increased risk of atherosclerosis and cardiovas-
cular disease.
Our results are consistent with previous data among
non-ESRD populations that report a strong association
between 25(OH) D deficiency and elevated markers of vas-
cular remodeling: Vitamin D supplementation of vitamin
D deficient, healthy British Bangladeshi adults resulted in
significant reductions in plasma MMP-9 and serum CRP
concentrations [20]. Vitamin D supplementation of
congestive heart failure patients significantly increased
serum concentrations of anti-inflammatory cytokine IL-10
and suppressed TNF-a synthesis over a nine month period
[6]. Further, previous reports show that anti-inflammatory
IL-10 is increased by vitamin D supplementation in vitro
and in mice [11]. Vitamin D acts on dendritic cells, T-
cells, and B-cells to enhance IL-10 expression [21-23].
While others have reported reductions in CRP con-
centrations following vitamin D supplementation
[5,6,24], and negative correlations between serum 25
Table 2 Characteristics of African American participants by vascular access type
Characteristic Arteriovenous fistula
(AVF)
Arteriovenous graft
(AVG)
Catheter
N = 38 N = 44 N = 9 p value
Age (years) 57.2 ± 13.0 60.8 ± 12.4 60.7 ± 9.6 0.41
Sex 0.07
Female 13 (34.2) 26 (29.9) 4 (44.4)
Male 25 (65.8) 18 (40.9) 5 (55.6)
Dialysis vintage (yrs) 4.9 ± 3.4 6.4 ± 4.5 6.1 ± 5.2 0.25
KT/V* 1.5 ± 0.4 1.4 ± 0.3 1.4 ± 0.2 0.49
Body mass index (kg/m2) 0.67
Under (<18.5) 0 (0.0) 0 (0.0) 1 (11.1)
Normal (18.5 to <25) 10 (28.6) 13 (30.9) 0 (0.0)
Overweight (25 to <30) 13 (37.1) 18 (42.9) 6 (66.7)
Obese (> = 30) 12 (34.3) 11 (26.2) 2 (22.2)
Smoking status 0.45
Never 21 (55.3) 31 (70.5) 3 (33.3)
Former 8 (21.0) 10 (22.7) 5 (55.6)
Current 9 (23.7) 3 (6.8) 1 (11.1)
Activated vitamin D treatment
29 (76.3) 34 (77.3) 8 (88.9) 0.70
Comorbidities
Diabetes 13 (34.2) 26 (59.1) 6 (66.7) 0.02
Hypertension 37 (97.4) 44 (100.0) 8 (88.9) 0.48
Stroke or TIA 2 (5.3) 11 (25.0) 3 (33.3) 0.03
Congestive heart failure 10 (26.3) 10 (22.7) 1 (11.1) 0.62
Peripheral arterial disease 4 (10.5) 8 (18.2) 2 (22.2) 0.60
HIV or AIDS 0 (0.0) 1 (2.3) 2 (22.2) <0.01
Laboratory tests
25(OH)D level (ng/ml) 21.6 ± 11.3 16.7 ± 7.3 17.1 ± 9.7 0.05
Calcium (mg/dl) 8.9 ± 0.8 8.7 ± 0.9 8.8 ± 1.1 0.65
Phosphorus (mg/dl) 5.5 ± 2.2 5.1 ± 1.6 5.5 ± 2.7 0.63
intact PTH (pg/dl) 401.6 ± 268.2 515.1 ± 693.0 624.4 ± 668.8 0.44
Albumin (g/dl) 4.1 ± 0.4 6.1 ± 0.2 3.7 ± 0.2 0.63
Alkaline Phosphatase (U/L) 115.4 ± 57.0 171.2 ± 146.6 120.9 ± 67.1 0.07
Hemoglobin (g/l) 12.13 ± 1.1 12.1 ± 1.6 11.0 ± 1.6 0.04
Total Cholesterol (mg/dl) 152.1 ± 31.2 153.7 ± 31.3 168.9 ± 46.4 0.42
Triglycerides (mg/dl) 132.4 ± 68.5 136.3 ± 82.1 121.4 ± 77.5 0.88
HDL cholesterol (mg/dl) 47.4 ± 20.5 48.6 ± 17.1 48.9 ± 27.2 0.96
LDL cholesterol (mg/dl) 79.3 ± 28.7 75.4 ± 32.3 95.6 ± 41.4 0.27
Results are expressed as number (%) or mean ± standard deviation
*KT/V = dialysis adequacy
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(OH)D concentration and TNF-a concentrations [4],
this was not observed in our study, possibly due to our
sample size or that a greater differential in 25(OH)D
concentration may be needed in order to observe an
association with these biomarkers. Whilst we identified
associations between both MMP-9 and IL-10 with 25
(OH) D concentration, we also observed several impor-
tant negative findings in this cross-sectional study fol-
lowing multivariate adjustment. First, while PTH
concentrations were greater among patients with 25
(OH)D < 15 ng/dL, they were not significantly different
among the vitamin D cohorts, as we would have
expected to observe, possibly due to our relatively small
sample size. Second, there was no significant association
observed between 25(OH) D and CRP, the most com-
mon biomarker of inflammation. This may be due to
our relatively small sample size, however, other cross-
sectional reports among non-ESRD populations have
also failed to find an association between 25(OH)D con-
centration and CRP concentration following multivariate
analysis, supporting our conclusion [4,14,18]. We did
not observe elevations in MMP-9 and CRP concentra-
tions as large as those reported previously in comparable
patients [25], likely because MMP-9 gene expression is
upregulated by several factors that were not included in
our analysis. Finally, while MMP-2 concentrations
tended to be higher with 25(OH)D concentrations <15
ng/dL, this did not reach significance, likely due to our
sample size.
MMP’s promote the remodeling of connective tissue
and basement membranes via degradation of collagen,
and act as important regulatory molecules in inflamma-
tion and vascular diseases. MMP-9 is released by neu-
trophils and is a key effector molecule of inflammatory
cells, aiding migration of inflammatory leukocytes
through tissue barriers, lysing protein substrates, modu-
lating smooth muscle cell migration, and promoting
angiogenesis [26,27]. MMP’s also regulate inflammation
by directly and indirectly acting on pro-inflammatory
cytokines, such as TNF-a and TGF-b, to control che-
mokine activity [27]. 25(OH)D may act to reduce MMP-
9 in several ways. An increase in IL-10 concentration, as
we observed, may also act to suppress MMP-9 secretion
[28]. Pulmonary tuberculosis in vitro studies suggest
that vitamin D blunts MMP-9 expression by inhibition
of c-Jun-N-terminal kinase(JNK) and NFkappaB signal-
ing cascades [9]. MMP-9 concentrations are increased in
the setting of several chronic inflammatory diseases, and
Figure 1 Correlation between serum 25(OH)D and MMP-9 concentration. Pearson correlation coefficient -0.29, P value = 0.004 Note:
Continuous line represents regression line and dashed lines represent 95% confidence intervals
Table 3 Distribution of inflammatory factors by serum 25(OH)D level
All patients 25(OH) D <15 ng/ml 25(OH) D ≥ 15 ng/ml P value
TNF- a (pg/ml) 8.7 ± 3.5 8.1 ± 2.9 9.0 ± 3.9 0.2
MMP-9 (pg/ml) 97517 ± 66188 115566 ± 66626 83981 ± 59392 0.01
MMP-2 (pg/ml) 548224 ± 156828 537353 ± 182886 488938 ± 165330 0.2
CRP (mg/L) 8.8 ± 16.0 10.5 ± 19.0 7.7 ± 13.0 0.03
IL-10 (pg/ml) 0.5 ± 0.6 0.4 ± 0.4 0.5 ± 0.6 0.6
Results are expressed as mean ± standard deviation
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MMP elevations are associated with abdominal aortic
aneurysm rupture [29] and acute myocardial infarction
[30]. These findings suggest that the risk for acquiring
or further progression of these disorders may be posi-
tively impacted by limiting MMP concentrations.
Another important finding of our study is that vascu-
lar access type modifies the relationship between plasma
MMP-9 and circulating 25(OH) D concentrations.
When we stratified AVF versus AVG, the association
between MMP-9 and 25(OH) D concentrations no
longer remained significant among AVF patients,
whereas the relationship remained significant among
patients using an AVG, suggesting that MMP-9 concen-
trations in AVF patients were too low for a relationship
with 25(OH)D to be detected. This may occur because
the prosthetic material within an AVG may induce
increased systemic inflammation. This finding is sup-
ported by data examining the role of vascular access
type on systemic inflammation among prevalent HD
patients, which noted that CRP concentrations were sig-
nificantly lower among autogenous AVF users compared
with patients using a prosthetic AVG [31].
Limitations of this study should be considered. First,
our relatively small sample size may affect our results,
however the 25(OH) D concentrations observed among
our subjects are comparable to those reported among
larger ESRD patient cohorts, and the observed inverse
association between 25(OH) D and MMP-9 has been
reported in a larger, non-renal patient cohort [18]. Sec-
ond, the cross-sectional design of our study does not
allow for causal inference. We cannot exclude the possi-
bility that an association exists between 25(OH) D and
the additional inflammatory biomarkers examined in
our study, but due to our relatively small sample size,
we may be underpowered to detect it. For example, the
power to detect a statistical difference, if any, between
25(OH)D groups was less than 50% for TNF-a and
MMP-2. Third, although we have attempted to reduce
the effect of confounding by limiting our study popula-
tion to include only patients free of infection or inflam-
mation, residual confounding inherent to the cross-
sectional design cannot be excluded.
Conclusions
In conclusion, the results of our study reveal a new find-
ing of a significant inverse relationship between plasma
MMP-9 and circulating 25(OH) D concentrations
among AA ESRD patients, and suggest that there may
be value in measuring 25(OH) D concentrations in
ESRD patients. In addition, we observed a positive asso-
ciation between 25(OH)D concentration and anti-
inflammatory IL-10 concentration. Our findings extend
data obtained from previous studies in linking low vita-
min 25(OH)D concentrations to elevated concentrations
of the cardiovascular risk marker, circulating MMP-9, in
ESRD patients. Given the high prevalence of nutritional
vitamin D deficiency and cardiovascular disease among
ESRD patients, our findings suggest that future studies
are warranted which further characterize the relation-
ship between nutritional vitamin D therapy and vascular
remodeling biomarker synthesis.
Figure 2 Difference in Log Concentration of MMP-9 by 25(OH)
D group.
Table 4 Adjusted* multivariate associations between 25(OH) D concentration and inflammatory markers
Model 1 Model 1 + vitamin D treatment
adjustment
Model 1 + vitamin D treatment + season
adjustment
Beta coefficient ± standard
error
P value Beta coefficient ± standard
error
P value Beta coefficient ± standard
error
P value
Log TNF-a (pg/ml) -0.003 ± 0.006 0.5 -0.002 ± 0.006 0.6 -0.003 ± 0.006 0.5
Log MMP-9 (pg/ml) -0.017 ± 0.008 0.04 -0.019 ± 0.008 0.02 -0.018 ± 0.008 0.03
Log MMP-2 (pg/ml) -0.003 ± 0.004 0.5 -0.004 ± 0.004 0.3 -0.004 ± 0.004 0.3
Log CRP (mg/ml) -0.013 ± 0.015 0.3 -0.014 ± 0.014 0.4 -0.013 ± 0.014 0.3
Log IL-10 (pg/ml) 0.022 ± 0.010 0.04 0.021 ± 0.010 0.04 0.021 ± 0.010 0.04
Model 1 is adjusted for smoking, gender, BMI, age, and diabetes
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